JP2022536901A5 - - Google Patents

Info

Publication number
JP2022536901A5
JP2022536901A5 JP2021573420A JP2021573420A JP2022536901A5 JP 2022536901 A5 JP2022536901 A5 JP 2022536901A5 JP 2021573420 A JP2021573420 A JP 2021573420A JP 2021573420 A JP2021573420 A JP 2021573420A JP 2022536901 A5 JP2022536901 A5 JP 2022536901A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
group
substituents
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037309 external-priority patent/WO2020252205A1/en
Publication of JP2022536901A publication Critical patent/JP2022536901A/ja
Publication of JP2022536901A5 publication Critical patent/JP2022536901A5/ja
Pending legal-status Critical Current

Links

JP2021573420A 2019-06-12 2020-06-11 統合的ストレス応答経路の阻害剤 Pending JP2022536901A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860676P 2019-06-12 2019-06-12
US62/860,676 2019-06-12
US201962943666P 2019-12-04 2019-12-04
US62/943,666 2019-12-04
PCT/US2020/037309 WO2020252205A1 (en) 2019-06-12 2020-06-11 Inhibitors of integrated stress response pathway

Publications (2)

Publication Number Publication Date
JP2022536901A JP2022536901A (ja) 2022-08-22
JP2022536901A5 true JP2022536901A5 (cg-RX-API-DMAC10.html) 2023-06-19

Family

ID=73781542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573420A Pending JP2022536901A (ja) 2019-06-12 2020-06-11 統合的ストレス応答経路の阻害剤

Country Status (12)

Country Link
US (1) US20210317102A1 (cg-RX-API-DMAC10.html)
EP (1) EP3983378A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022536901A (cg-RX-API-DMAC10.html)
KR (1) KR20220024486A (cg-RX-API-DMAC10.html)
CN (1) CN114206829A (cg-RX-API-DMAC10.html)
AU (1) AU2020293226A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021024431A2 (cg-RX-API-DMAC10.html)
CA (1) CA3142497A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021003247A1 (cg-RX-API-DMAC10.html)
IL (1) IL288747A (cg-RX-API-DMAC10.html)
MX (1) MX2021015210A (cg-RX-API-DMAC10.html)
WO (1) WO2020252205A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
WO2022256609A1 (en) * 2021-06-03 2022-12-08 Altos Labs, Inc. Modulators of integrated stress response pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
US7544690B2 (en) * 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
WO2009151800A1 (en) * 2008-05-07 2009-12-17 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds
EP2531490B1 (en) * 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
TW201808888A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑

Similar Documents

Publication Publication Date Title
JP2022536663A5 (cg-RX-API-DMAC10.html)
JP2022521605A5 (cg-RX-API-DMAC10.html)
Wrobleski et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165
JP2021527044A5 (cg-RX-API-DMAC10.html)
JP7366456B2 (ja) インターフェロン遺伝子刺激因子stingのアゴニスト
RU2020122711A (ru) Ингибиторы пути интегрированной реакции на стресс
JP6666263B2 (ja) グルタミナーゼの新規阻害剤
US20240293418A1 (en) Combination therapy for treating cancer
TWI683825B (zh) 單鏈trail-受體激動劑蛋白質
JP2022536901A (ja) 統合的ストレス応答経路の阻害剤
US20100113520A1 (en) Kinase knockdown via electrophilically enhanced inhibitors
JP2022536663A (ja) 統合的ストレス応答経路のモジュレーター
JP2018113988A (ja) IL−1βへの結合メンバー
CN108137672B (zh) 用于生产具有igg fc结构域的融合蛋白的方法
CA2889756A1 (en) Thiohydantoin compounds as androgen receptor modulators
JP2021527044A (ja) 統合的ストレス応答経路の阻害剤
CN105399685A (zh) 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
WO2020033782A1 (en) Activators of the retinoic acid inducible gene "rig-1" pathway and methods of use thereof
TW202432124A (zh) 蛋白質酪胺酸磷酸酶抑制劑、其組合物及使用方法
WO2023192801A1 (en) Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
CN113164492A (zh) 用于治疗癌症的nupr1抑制
AU2016341402A1 (en) Single-chain GITR-receptor agonist proteins
Bakherad et al. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity
RU2022100043A (ru) Ингибиторы пути интегрированной реакции на стресс
KR20230022457A (ko) Akt3 조절제